Ivabradine Monotherapy in Pediatric Patients with Focal Atrial Tachycardia: a Single-center Study

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2023 Mar 4

PMID 36869903

Authors

Xinyi Xu

Ying Guo

Wei Gao

Meirong Huang

Tingliang Liu

Fen Li

Affiliations

Soon will be listed here.

Abstract

Conclusion: Ivabradine is well-tolerated and may provide early heart rate control in pediatric FAT and can be considered early, especially in the presence of left ventricular dysfunction. Further investigations are deserved to confirm the optimal dose and long-term efficacy in this population.

What Is Known: • Focal atrial tachycardia (FAT) is the most common arrhythmia associated with tachycardia-induced cardiomyopathy (TIC) in children, and the efficacy of conventional antiarrhythmic medications in the treatment of FAT is poor. • Ivabradine is currently the only selective hyperpolarization-activated cyclic nucleotide-gated (HCN) inhibitor, which can effectively low HR without negative effect on blood pressure or inotropy.

What Is New: • Ivabradine (0.1-0.2 mg/kg every 12 h) can effectively suppress focal atrial tachycardia in 50% of pediatric patients. • Ivabradine provides early control of heart rate and hemodynamic stabilization in children with severe left ventricular dysfunction due to atrial tachycardia within 48 h.

Citing Articles

Ivabradine in treatment of symptomatic heart failure and supraventricular tachycardias in patients under six months of age.

Gomez-Ganda L, Parramon-Teixido C, Giralt-Garcia G, Fernandez-Garcia C, Ferrer-Menduina Q, Cabanas-Poy M Front Pharmacol. 2025; 16:1502375.

PMID: 40041489 PMC: 11876114. DOI: 10.3389/fphar.2025.1502375.

Ivabradine for Incessant Atrial Tachycardia in a 1-Year-Old Child After Tetralogy of Fallot Repair.

Balweel H, Sukardi R, Marwali E, Eri R, Tafriend N, Harsoyo A Case Rep Cardiol. 2025; 2025:2601345.

PMID: 39963303 PMC: 11832250. DOI: 10.1155/cric/2601345.

Tachycardia-Induced Cardiomyopathy: A Case Series and a Literature Review.

Abozaid W, Wong S, Deyell M, Sanatani S, Vijayashankar S CJC Pediatr Congenit Heart Dis. 2025; 3(6):272-284.

PMID: 39959626 PMC: 11827027. DOI: 10.1016/j.cjcpc.2024.10.007.

Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy.

Alijanzadeh D, Moghim S, Zarand P, Akbarzadeh M, Zarinfar Y, Khaheshi I Cardiovasc Drugs Ther. 2024; .

PMID: 39656365 DOI: 10.1007/s10557-024-07652-3.

[Research progress in the application of ivabradine in children with cardiovascular diseases].

Jiang L Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(7):782-788.

PMID: 39014957 PMC: 11562043. DOI: 10.7499/j.issn.1008-8830.2401072.

References

Michel H, Heissenhuber F, Wellmann S, Melter M, Gerling S . Ectopic Atrial Tachycardia in a 12-Month-Old Girl Treated With Ivabradine and Beta-Blocker, a Case Report. Front Pediatr. 2020; 8:313. PMC: 7308433. DOI: 10.3389/fped.2020.00313. View

Karmegaraj B, Balaji S, Raju P, Subramanian P, Subramanian R, Ibrahim S . Tachycardia-induced cardiomyopathy secondary to incessant ectopic atrial tachycardia in two infants: Potential new indication for early initiation of enteral ivabradine. Ann Pediatr Cardiol. 2021; 14(3):422-427. PMC: 8457284. DOI: 10.4103/apc.apc_37_21. View

Hackett G, Lin T, Imundo J . Use of ivabradine in a critically ill pediatric patient with recalcitrant ectopic atrial tachycardia and complex congenital heart disease. HeartRhythm Case Rep. 2022; 8(6):415-419. PMC: 9237372. DOI: 10.1016/j.hrcr.2022.03.011. View

Kang K, Etheridge S, Kantoch M, Tisma-Dupanovic S, Bradley D, Balaji S . Current management of focal atrial tachycardia in children: a multicenter experience. Circ Arrhythm Electrophysiol. 2014; 7(4):664-70. DOI: 10.1161/CIRCEP.113.001423. View

Kistler P, Chieng D, Tonchev I, Sugumar H, Voskoboinik A, Schwartz L . P-Wave Morphology in Focal Atrial Tachycardia: An Updated Algorithm to Predict Site of Origin. JACC Clin Electrophysiol. 2021; 7(12):1547-1556. DOI: 10.1016/j.jacep.2021.05.005. View

Medi C, Kalman J, Haqqani H, Vohra J, Morton J, Sparks P . Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009; 53(19):1791-7. DOI: 10.1016/j.jacc.2009.02.014. View

Arvind B, Kothari S, Juneja R, Saxena A, Ramakrishnan S, Gupta S . Ivabradine Versus Amiodarone in the Management of Postoperative Junctional Ectopic Tachycardia: A Randomized, Open-Label, Noninferiority Study. JACC Clin Electrophysiol. 2021; 7(8):1052-1060. DOI: 10.1016/j.jacep.2021.01.020. View

Chen C, Kaur G, Mehta P, Morrone D, Godoy L, Bangalore S . Ivabradine in Cardiovascular Disease Management Revisited: a Review. Cardiovasc Drugs Ther. 2021; 35(5):1045-1056. DOI: 10.1007/s10557-020-07124-4. View

Mathew S, Po S, Thadani U . Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2017; 15(2):240-247. DOI: 10.1016/j.hrthm.2017.10.004. View

10.

Bohora S, Lokhandwala Y, Parekh P, Vasavda A . Reversal of tachycardiomyopathy due to left atrial tachycardia by ivabradine. J Cardiovasc Electrophysiol. 2010; 22(3):340-2. DOI: 10.1111/j.1540-8167.2010.01860.x. View

11.

Janson C, Tan R, Iyer V, Vogel R, Vetter V, Shah M . Ivabradine for treatment of tachyarrhythmias in children and young adults. HeartRhythm Case Rep. 2019; 5(6):333-337. PMC: 6587055. DOI: 10.1016/j.hrcr.2019.03.007. View

12.

Cohen M, Cohen J, Shope C, Stollar L, Collazo L . Ivabradine as a stabilising anti-arrhythmic agent for multifocal atrial tachycardia. Cardiol Young. 2020; 30(6):899-902. DOI: 10.1017/S1047951120001195. View

13.

Bonnet D, Berger F, Jokinen E, Kantor P, Daubeney P . Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. J Am Coll Cardiol. 2017; 70(10):1262-1272. DOI: 10.1016/j.jacc.2017.07.725. View

14.

Fleming S, Thompson M, Stevens R, Heneghan C, Pluddemann A, Maconochie I . Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies. Lancet. 2011; 377(9770):1011-8. PMC: 3789232. DOI: 10.1016/S0140-6736(10)62226-X. View